3-Amino-benzo[d]isoxazoles as Novel Multitargeted Inhibitors of Receptor Tyrosine Kinases

Citations Over Time

Abstract

A series of benzoisoxazoles and benzoisothiazoles have been synthesized and evaluated as inhibitors of receptor tyrosine kinases (RTKs). Structure-activity relationship studies led to the identification of 3-amino benzo[ d]isoxazoles, incorporating a N, N'-diphenyl urea moiety at the 4-position that potently inhibited both the vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor families of RTKs. Within this series, orally bioavailable compounds possessing promising pharmacokinetic profiles were identified, and a number of compounds demonstrated in vivo efficacy in models of VEGF-stimulated vascular permeability and tumor growth. In particular, compound 50 exhibited an ED 50 of 2.0 mg/kg in the VEGF-stimulated uterine edema model and 81% inhibition in the human fibrosarcoma (HT1080) tumor growth model when given orally at a dose of 10 mg/kg/day.

Related Papers

• → TNP‐470 Suppresses the Tumorigenicity of HT1080 Fibrosarcoma TumorThrough the Inhibition of VEGF Secretion From the Tumor Cells(2001)11 cited
• → In vitro decreases of the fibrinolytic potential of cultured human fibrosarcoma cell line, HT1080, by Nigella sativa oil(2004)44 cited
• → DNA aptamer S11e recognizes fibrosarcoma and acts as a tumor suppressor(2021)17 cited
• → Intensive fibrosarcoma-binding capability of the reconstituted analog and its antitumor activity(2017)6 cited
• [Effect of tissue factor in extravascular migration of fibrosarcoma cells].(2011)